Obizur

Indicated For

acquired hemophilia A

About This Medication

# Takeda Patient Assistance Program Guide: How to Get Obizur (susoctocog alfa) at Low or No Cost Obizur (susoctocog alfa) is a specialized medication for adults with acquired hemophilia A, and Takeda's patient assistance program can help eligible patients access it at little or no cost if you face financial challenges.[2][3] ## About Obizur and Acquired Hemophilia A **Acquired hemophilia A (AHA)** is a rare bleeding disorder that develops in adulthood, unlike congenital hemophilia which is present from birth. It occurs when the body produces antibodies (inhibitors) that attack its own factor VIII, a crucial blood clotting protein, leading to uncontrolled bleeding episodes.[2][5][7] Obizur contains **susoctocog alfa**, a recombinant (lab-made) version of factor VIII derived from a porcine (pig) sequence. This modified protein evades human antibodies better, helping to control bleeds effectively.[2][3][6] Obizur is FDA-approved for **on-demand treatment of bleeding episodes** in adults with AHA, administered via intravenous (IV) injection under medical supervision, often in a hospital or clinic.[2][3] It's not for routine prophylaxis or congenital hemophilia with inhibitors.[3][7] Typical dosing starts at 200 units per kg body weight for severe bleeds, adjusted based on factor VIII activity levels monitored via blood tests (aiming for 100-200 U/dL initially).[2][3][5] Each vial is 500 units, often requiring multiple vials per dose.[4] **Important warnings**: Obizur contains traces of hamster and mouse proteins, so it's contraindicated if you're allergic to these or susoctocog alfa. Stop use immediately if hypersensitivity signs like hives, chest tightness, or anaphylaxis occur.[1][3][7] Treatment requires a doctor's oversight experienced in hemophilia care.[2][3] ## Who Qualifies for Takeda's Assistance Program? Takeda Pharmaceuticals, the manufacturer of Obizur, offers patient assistance programs (PAPs) to uninsured or underinsured U.S. patients struggling with costs. While specific details like exact income thresholds aren't publicly detailed here, Takeda's programs typically target those at or below **400-500% of the Federal Poverty Level (FPL)**, though this varies.[2] Eligibility often includes: - U.S. residents (citizens or legal residents). - Diagnosis of AHA confirmed by a doctor. - Limited or no prescription insurance coverage. - Household income meeting program guidelines. Contact Takeda directly for personalized eligibility, as programs evolve.[2] ## Income Eligibility Breakdown | Household Size | Annual Income Threshold (Estimated, up to 400-500% FPL) | Notes | |---------------|---------------------------------------------------------|-------| | Individual | $60,000 - $75,000 | Varies by program; confirm with Takeda | | Couple | $80,000 - $100,000 | Includes all household income | | Family of 3 | $100,000 - $125,000 | Assets may be considered | | Family of 4 | $120,000 - $150,000 | Higher for larger families | *These are general estimates based on common PAP structures; actual thresholds require verification via Takeda's application process. FPL adjusts annually.*[2] ## Insurance Requirements Most PAPs, including Takeda's, require that you: - Be uninsured or have insurance that doesn't cover Obizur fully (e.g., high copays/deductibles). - Not be eligible for federal programs like Medicaid (though some bridge gaps). - **Medicare patients**: Often ineligible for free drug via PAPs, but Takeda's copay assistance or bridge programs may help Part D enrollees with costs above the donut hole or during coverage gaps. Exhaust insurance options first.[2] ## Step-by-Step Application Process 1. **Consult your doctor**: Discuss Obizur need and get a prescription. Your hemophilia specialist or hematologist must confirm AHA diagnosis and provide clinical details.[2][5] 2. **Gather documents**: Proof of income (tax returns, pay stubs), insurance status (denial letter if applicable), ID, prescription, and diagnosis proof.[2] 3. **Contact Takeda**: Call the PAP hotline (typically 1-877-825-3327 or similar; check takeda.com/assistance) or visit their patient support portal to start application.[2] 4. **Submit application**: Doctor completes clinical sections; patient handles financials. Online, mail, or fax options available. 5. **Await approval**: Processing takes 2-4 weeks typically. 6. **Receive medication**: Shipped to your doctor's office or home.[2] ## Timeline and Delivery - **Processing time**: 1-4 weeks from submission, faster for urgent bleeds.[2] - **Delivery**: Free shipping to prescriber's office or pharmacy; some direct-to-patient. Refrigerated storage required.[3][4] - **Supply duration**: 1-3 months initially, based on need; refills require reauthorization.[2] Monitor factor VIII levels closely during treatment, with reassessment at 24-48 hours.[5] ## Alternatives if Denied or Other Options If denied: - Appeal with additional documents. - Explore state assistance, hemophilia organizations (e.g., NHF), or generic factor therapies. - **Biosimilars/alternatives**: No direct biosimilars listed for susoctocog alfa; consider bypassing agents like FEIBA or NovoSeven for AHA bleeds if Obizur ineffective.[5] - Patient Access Network (PAN) Foundation or HealthWell Foundation grants. - Clinical trials via clinicaltrials.gov.[2][5] ## Disclaimer This guide provides general information based on available sources as of 2026 and is not medical or financial advice. Eligibility, terms, and availability change; always verify with Takeda (takeda.com or 1-877-TAKEDA-8). Consult your healthcare provider for personalized treatment. Obizur use carries risks like inhibitor development or hypersensitivity—discuss thoroughly. Takeda disclaims liability for decisions based on this guide.[1][2][3]

Program information last verified: March 30, 2026